Strains of lactic acid bacteria for preventing necrotizing enterocolitis
The present invention relates to novel strains of lactic acid bacteria, Lactobacillus plantarum subsp. plantarum PM-A0087 deposited as NRRL accession number B-50523, Bifidobacterium longum PM-A0101 deposited as NRRL accession number B-50525, and Bifidobacterium bifidum PM-A0218 deposited as NRRL accession number B-50524.
1. An isolated biologically pure culture of a lactic acid bacteria strain selected from the group consisting of:
Lactobacillus plantarum subsp. plantarum PM-A0087 deposited as NRRL accession number B-50523;
Bifidobacterium longum PM-A0101 deposited as NRRL accession number B-50525; and
Bifidobacterium bifidum PM-A0218 deposited as NRRL accession number B-50524.
2. A composition, comprising an isolated biologically pure culture of Lactobacillus plantarum subsp. plantarum PM-A0087 deposited as NRRL accession number B-50523, Bifidobacterium longum PM-A0101 deposited as NRRL accession number B-50525, Bifidobacterium bifidum PM-A0218 deposited as NRRL accession number B-50524, or a combination thereof.
3. The composition according to claim 2 , comprising a biologically pure culture of Lactobacillus plantarum subsp. plantarum PM-A0087 deposited as NRRL accession number B-50523, a biologically pure culture of Bifidobacterium longum PM-A0101 deposited as NRRL accession number B-50525, and a biologically pure culture of Bifidobacterium bifidum PM-A0218 deposited as NRRL accession number B-50524.
4. The composition according to claim 2 , comprising a biologically pure culture of Lactobacillus plantarum subsp. plantarum PM-A0087 deposited as NRRL accession number B-50523, a biologically pure culture of Bifidobacterium longum PM-A0101 deposited as NRRL deposit number B-50525, and a biologically pure culture of Bifidobacterium bifidum PM-A0218 deposited as NRRL deposit number B-50524 respectively, wherein the composition comprises an equal number of cells from each biologically pure culture.
5. The composition according to claim 2 , wherein each of the biologically pure cultures of the strains contains 0.1−10×10 9 CFU/ml bacteria.
6. The composition according to claim 5 , wherein each of the biological pure cultures of the strains contains about 1×10 9 CFU/ml bacteria.
7. The composition according to claim 5 , wherein each of the biological pure cultures of the strains contains about 1.5×10 9 CFU/ml bacteria.
8. The composition according to claim 2 for oral administration.
9. The composition according to claim 2 , which is a pharmaceutical composition.
10. The composition according to claim 2 , which is a dietary composition.